Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vemurafenib + KTN3379
- Development stage
- Unknown
- Lead developer
- Celldex Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Vemurafenib + KTN3379 is an investigational combination therapy comprising vemurafenib, a small molecule BRAF kinase inhibitor, and KTN3379 (also known as CDX-3379), a human monoclonal antibody targeting HER3 (ErbB3). The combination is designed to provide dual pathway inhibition in cancers driven by BRAF mutations, specifically addressing resistance mechanisms mediated by HER3 upregulation, which may limit the efficacy of BRAF inhibition alone. Preclinical and pilot clinical studies focused on BRAF^V600E^ mutated, radioiodine-refractory thyroid carcinoma, with the aim of restoring radioactive iodine (RAI) uptake in these patients. Vemurafenib inhibits BRAF activity in the MAPK signaling pathway, while KTN3379 blocks HER3, potentially enhancing redifferentiation and RAI incorporation for targeted radiotherapy[1][4][7]. The combination has not received regulatory approval and has been evaluated in early-phase clinical trials.
- Brand names
- Zelboraf
- Other names
- vemurafenib + CDX-3379
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)BRAF V600E
Beyond the preview
Go deeper on vemurafenib + KTN3379.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vemurafenib + KTN3379.